D. Williams

发表

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

E. H. Thompson, M. Gooderham, K. Reich, 2019, The Lancet.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo‐controlled trial

B. Elewski, K. Papp, Y. Poulin, 2018, Journal of the American Academy of Dermatology.

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

K. Papp, M. Seyger, K. Unnebrink, 2019, The British journal of dermatology.

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

A. Kimball, C. Zouboulis, G. Jemec, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

M. Gooderham, K. Papp, A. Blauvelt, 2020, JAMA dermatology.

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

K. Papp, K. Unnebrink, D. Thaçi, 2017, The Lancet.

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis‐Related Arthritis, Psoriasis, and Crohn's Disease

J. Hyams, A. Lazar, D. Williams, 2018, The Journal of pediatrics.

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.

A. Menter, K. Papp, Jashin J. Wu, 2015, Journal of the American Academy of Dermatology.

Long‐term adalimumab efficacy in patients with moderate‐to‐severe hidradenitis suppurativa/acne inversa: 3‐year results of a phase 3 open‐label extension study

C. Zouboulis, G. Jemec, P. Foley, 2019, Journal of the American Academy of Dermatology.

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

W. Gulliver, S. Forman, A. Armstrong, 2019, The British journal of dermatology.

A GENETIC VARIANT IN THE BCL2 GENE ASSOCIATES WITH ADALIMUMAB RESPONSE IN HIDRADENITIS SUPPURATIVA CLINICAL TRIALS AND REGULATES EXPRESSION OF BCL2.

Jacob F. Degner, R. Kirsner, J. Waring, 2020, The Journal of investigative dermatology.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

A. Gottlieb, A. Kimball, A. Armstrong, 2016, The New England journal of medicine.

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

B. Strober, D. Williams, J. Crowley, 2011, The British journal of dermatology.

Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study

H. Nakagawa, Y. Hasegawa, S. Imafuku, 2018, The Journal of dermatology.

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.

A. Armstrong, M. Skup, L. Puig, 2020, JAMA dermatology.

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

B. Strober, A. Gottlieb, K. Papp, 2012, The Journal of investigative dermatology.

Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa

A. Nader, N. Mostafa, D. Williams, 2017, Clinical Pharmacokinetics.

Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study

K. Papp, M. Sundaram, Yihua Gu, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

F. Kerdel, C. Leonardi, A. Gottlieb, 2011, The British journal of dermatology.

15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

T. Bieber, P. Biswas, H. Valdez, 2020 .

Changes in C‐reactive protein in patients with moderate‐to‐severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy

B. Strober, Y. Poulin, D. Williams, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

A. Gottlieb, A. Kimball, A. Armstrong, 2016, The New England journal of medicine.